Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis

Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis

Molecular precision oncology faces two major challenges: first, to identify relevant and actionable molecular variants in a rapidly changing field and second, to provide access to a broad patient population. Here, we report a four-year experience of the Molecular Tumor Board (MTB) of the Comprehensi...

Full description

Bibliographic Details
Main Authors: Rouven Hoefflin, Adriana Lazarou, Maria Elena Hess, Meike Reiser, Julius Wehrle, Patrick Metzger, Anna Verena Frey, Heiko Becker, Konrad Aumann, Kai Berner, Martin Boeker, Nico Buettner, Christine Dierks, Jesus Duque-Afonso, Michel Eisenblaetter, Thalia Erbes, Ralph Fritsch, Isabell Xiang Ge, Anna-Lena Geißler, Markus Grabbert, Steffen Heeg, Dieter Henrik Heiland, Simone Hettmer, Gian Kayser, Alexander Keller, Anita Kleiber, Alexandra Kutilina, Leman Mehmed, Frank Meiss, Philipp Poxleitner, Justyna Rawluk, Juri Ruf, Henning Schäfer, Florian Scherer, Khalid Shoumariyeh, Andreas Tzschach, Christoph Peters, Tilman Brummer, Martin Werner, Justus Duyster, Silke Lassmann, Cornelius Miething, Melanie Boerries, Anna L. Illert, Nikolas von Bubnoff
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cancers
Subjects:
personalized cancer medicine
precision oncology
molecular profiling
molecular tumor board
targeted therapies
combination therapies
Online Access:https://www.mdpi.com/2072-6694/13/5/1151

Internet

https://www.mdpi.com/2072-6694/13/5/1151

Similar Items